Isolated pulmonary vasculitis associated with nilotinib use: A case report

Nicolette T Morris; Mihaela B Taylor; Melkon Hacobian; Olga M Olevsky; Tanaz A Kermani

doi:10.1016/j.lrr.2020.100214

Isolated pulmonary vasculitis associated with nilotinib use: A case report

Leuk Res Rep. 2020 Jun 18:14:100214. doi: 10.1016/j.lrr.2020.100214. eCollection 2020.

Authors

Nicolette T Morris¹, Mihaela B Taylor¹, Melkon Hacobian², Olga M Olevsky³, Tanaz A Kermani¹

Affiliations

¹ Division of Rheumatology, University of California, Los Angeles, David Geffen School of Medicine, California, USA.
² University of California, Los Angeles, David Geffen School of Medicine, California, USA.
³ Division of Hematology, University of California, Los Angeles, David Geffen School of Medicine, California, USA.

Abstract

An association between tyrosine-kinase inhibitor therapy for chronic myeloid leukemia and vascular adverse events including peripheral arterial disease, coronary artery disease, and pulmonary hypertension has been described. We present a patient who developed isolated pulmonary artery vasculitis resulting in left pulmonary artery stenosis, in addition to left coronary artery stenosis while on nilotinib. While monitoring for cardiovascular events is important, clinicians should also recognize possible drug-induced vasculitis during chronic nilotinib therapy.

Keywords: Arteritis; Chronic myeloid leukemia; Large vessel vasculitis; Nilotinib; Pulmonary arteritis; Pulmonary vasculitis; Tyrosine kinase inhibitor; Vascular adverse events; Vasculitis.